Jeremiah Boles

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer

Bert H. O’Neil, Aaron J. Scott, W.W. Ma et al. · Annals of Oncology · 2015 · 140 citations · Full text

Oncology, Pancreatic Cancer, Gastrointestinal Oncology +9

Pre-analytical and analytical variables affecting the measurement of plasma-derived microparticle tissue factor activity

R.D. Lee, D. Anthony Barcel, Julie Williams et al. · Thrombosis Research · 2011 · 116 citations · Full text

Tissue Engineering, Engineering, Medicine +10

Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer

Hanna K. Sanoff, Dominic H. Moon, Dominic T. Moore et al. · Nanomedicine Nanotechnology Biology and Medicine · 2019 · 60 citations · Full text

Radiation Therapy, Medicine, Nano-camptothecin Crlx101 +8

Anthracycline treatment of the human monocytic leukemia cell line THP-1 increases phosphatidylserine exposure and tissue factor activity

Jeremiah Boles, Julie Williams, Rachel M. Hollingsworth et al. · Thrombosis Research · 2011 · 46 citations

Inflammation, Cytokine, Malignant Blood Disorder +8

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

Aaron J. Scott, Bert H. O’Neil, Wen Wee et al. · Journal of Clinical Oncology · 2015 · 10 citations

Multiplex Genetic Testing, Pathology, Pharmacotherapy +17